110 related articles for article (PubMed ID: 3112715)
1. [Evaluation of the specific activity of hyperimmune anti-Pseudomonas aeruginosa human plasma in an experiment].
Podgornaia LG; Shinkarenko AA; Krokhina MA; Dziuban NF; D'iachenko VF
Patol Fiziol Eksp Ter; 1987; (2):70-2. PubMed ID: 3112715
[No Abstract] [Full Text] [Related]
2. Study of Pseudomonas haemolysin. III. Properties of antilysin serum.
Lochmann O; Výmola F
J Hyg Epidemiol Microbiol Immunol; 1975; 19(2):224-9. PubMed ID: 809503
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa antibodies in human plasma.
Doi T; Yoshioka M; Nakajima T
Jpn J Exp Med; 1976 Jun; 46(3):149-54. PubMed ID: 60502
[TBL] [Abstract][Full Text] [Related]
4. [Protective action of various antibody preparations in experimental bacterial sepsis].
Trautmann M; Brückner O; Hofstaetter T; Seiler FR; Hahn H
Beitr Infusionther Klin Ernahr; 1982; 9():155-65. PubMed ID: 6816213
[No Abstract] [Full Text] [Related]
5. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
6. [Donor plasma with anti-Pseudomonas aeruginosa activity as a directed-action preparation].
Nazarchuk LV
Vrach Delo; 1987 Jul; (7):96-8. PubMed ID: 3114958
[No Abstract] [Full Text] [Related]
7. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study of the protective properties of native and sorbed Pseudomonas aeruginosa anatoxins].
Dziuban NF
Mikrobiol Zh (1978); 1983; 45(6):85-7. PubMed ID: 6443863
[No Abstract] [Full Text] [Related]
9. [The protective effect of anti-Pseudomonas blood preparations].
Nazarchuk LV; Koval' AI
Fiziol Zh (1994); 2001; 47(6):55-7. PubMed ID: 11962093
[TBL] [Abstract][Full Text] [Related]
10. [Protective effect of Pseudomonas-specific immunoglobulin from the rabbit and of active immunization in experimental Pseudomonas sepsis in mice].
Trautmann M; Brückner O; Hahn H
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jul; 252(3):370-83. PubMed ID: 6215803
[TBL] [Abstract][Full Text] [Related]
11. Passive hemagglutination reaction using formalinized sheep erythrocytes treated with tannic acid and coated with exotoxin of Pseudomonas aeruginosa.
Takeshi K; Homma JY
Jpn J Exp Med; 1978 Dec; 48(6):497-501. PubMed ID: 108439
[TBL] [Abstract][Full Text] [Related]
12. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of properties of Pseudomonas aeruginosa recombinant outer membrane protein F (OprF)].
Zlygostev SA; Gataullin AG; Kaloshin AA; Mikhaĭlova NA; Zverev VV
Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):43-7. PubMed ID: 17297879
[TBL] [Abstract][Full Text] [Related]
14. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
15. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
16. Anti-pseudomonas activity of anti-lipopolysaccharide hyperimmune equine plasma.
Wells M; Gaffin SL
Clin Exp Immunol; 1987 Apr; 68(1):86-92. PubMed ID: 3115643
[TBL] [Abstract][Full Text] [Related]
17. [Use of a polyvalent erythrocyte diagnostic agent for determining antibodies to Pseudomonas aeruginosa in clinical practice].
Aleksandrova IA; Titova TI; Aleksandrov AD; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1989 Jan; (1):46-50. PubMed ID: 2496541
[TBL] [Abstract][Full Text] [Related]
18. [The production and use of plasma against Pseudomonas aeruginosa infection].
Popov SD; Ryzhkov SV; Stanislavskiĭ ES; Plakhotnikov AIa; Gurevich KIa; Sergienko AI; Zaĭchik VI; Popova NN; Fedorova GM; Edvabnaia LS
Voen Med Zh; 1990 Dec; (12):30-1. PubMed ID: 2127965
[No Abstract] [Full Text] [Related]
19. [Production of a hyperimmune antitoxic donor plasma against Pseudomonas aeruginosa].
Krokhina MA; Davatdarova GM; Cherkas GP; Podgornaia LG; Shinkarenko AA
Zh Mikrobiol Epidemiol Immunobiol; 1980 Sep; (9):78-83. PubMed ID: 6778040
[TBL] [Abstract][Full Text] [Related]
20. Passive hemagglutination reaction test using formalinized sheep erythrocytes treated with tannic acid and coated with proteast or elastase of Pseudomonas aeruginosa.
Homma JY; Tomiyama T; Sano H; Hirao Y; Saku K
Jpn J Exp Med; 1975 Oct; 45(5):361-5. PubMed ID: 817055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
